当前位置：
首页
>
产品中心 >
Functional_antibody >
Adipogen/anti-CD40L (human), mAb (rec.) (blocking) (hu5c8) (preservative free)/AG-27B-6002PF-C100/100 µg
Adipogen/anti-CD40L (human), mAb (rec.) (blocking) (hu5c8) (preservative free)/AG-27B-6002PF-C100/100 µg
商品编号：
AG-27B-6002PF-C100
品牌：
Adipogen Inc
市场价：
¥7600.00
美元价：
4560.00
产品分类：
功能性抗体
公司分类：
Functional_antibody
联系Q Q：
3392242852
电话号码：
4000-520-616
电子邮箱：
info@ebiomall.com
商品介绍
| ProductDetails | |
|---|---|
| Synonyms | CD40Ligand;CD154;TumorNecrosisFactorLigandSuperfamilyMember5;TNFSF5;Gp39;TRAP |
| ProductType | RecombinantAntibody |
| Properties | |
| Clone | hu5c8 |
| Isotype | HumanIgG1κ |
| Immunogen/Antigen | RecombinanthumanCD40L. |
| Label/Conjugates | PreservativeFree |
| Application | FlowCytometry:1µg/ml FunctionalApplication(Blocking):NeutralizesCD40LfunctionbyblockingtheinteractionbetweenCD40andCD40Linvitroandinvivo. WesternBlot:1µg/ml Optimalconditionsshouldbedeterminedindividuallyforeachapplication. |
| Crossreactivity | Dog Human |
| Specificity | RecognizesandbindshumanCD40LwithanIC50of0.845µg/ml.Cross-reactswithcanineCD40L. |
| Purity | ≥95%(SDS-PAGE) |
| PurityDetail | ProteinA-affinitypurified. |
| EndotoxinContent | <0.001eu mu;g=""> |
| Concentration | 1mg/ml |
| Formulation | Liquid.InPBS. |
| AccessionNumber | UniProtIDP29965 |
| OtherProductData | ThisantibodyisabiosimilarcalledRuplizumab(Antova;BG9588)andoriginallydevelopedbyBiogen.RuplizumabisaCD40ligandblockerdesignedforthetreatmentofrheumaticdiseaseslikesystemiclupuserythematosusandlupusnephritis,butwithdrawnfromclinicaltrialsduetosideeffects. |
| ShippingandHandling | |
| Shipping | BLUEICE |
| ShortTermStorage | +4°C |
| LongTermStorage | -20°C |
| HandlingAdvice | Avoidfreeze/thawcycles. |
| Use/StABIlity | Stableforatleast1yearafterreceiptwhenstoredat-20°C. Stableforatleast3monthsafterreceiptwhenstoredat+4°C. |
| Documents | |
| MSDS |  DownloadPDF |
| ProductSpecificationSheet | |
| Datasheet | DownloadPDF |
CD40Ligand(CD40L),renamedTNFSF5butnowalsoknownasCD154,TRAPandgp39,isa34-39kDatypeIItransmembraneglycoprotein,thatbelongstotheTNFsuperfamily,andasurfacereceptorexpressedonactivatedTcellswhichactsasacostimulatorymoleculetotriggerimmuneresponses.CD40LbindstoCD40,whichisessentialinmediatingabroadvarietyofimmuneandinflammatoryresponsesincludingTcell-dependentimmunoglobulinclassswitching,memoryBcelldevelopmentandgerminalcenterformation.CD40isconstitutivelyexpressedbyantigenpresentingcells,includingdendriticcells,Bcellsandmacrophages.Consistentwithitswidespreadexpressiononnormalcells,CD40isalsoexpressedonawiderangeoftumorcells.CD40Llevelsareincreasedinserumandininflamedtissuesofpatientswithautoimmunediseases.
ProductReferences
- Pharmacokinetics/dynamicsof5c8,amonoclonalantibodytoCD154(CD40ligand)suppressionofanimmuneresponseinmonkeys:J.VGobburu,etal.;JPET286,925(1998)
- TreatmentwithhumanizedmonoclonalantibodyagainstCD154preventsacuterenalallograftrejectioninnonhumanprimates:A.D.Kirk,etal.;Nat.Med.5,686(1999)
- Long-termsurvivalandfunctionofintrahepaticisletallograftsinrhesusmonkeystreatedwithhumanizedanti-CD154:N.S.Kenyon,etal.;PNAS96,8132(1999)
- Long-termsurvivalandfunctionofintrahepaticisletallograftsinbaboonstreatedwithhumanizedanti-CD154:N.S.Kenyon,etal.;Diabetes48,1473(1999)
- ProlongationofprimatecardiacallograftsurvivalbytreatmentwithANTI-CD40ligand(CD154)antibody:R.N.Pierson,etal.;Transplantation68,1800(1999)
- StructureofCD40ligandincomplexwiththeFabfragmentofaneutralizinghumanizedantibody:M.Karpusas,etal.;Structure9,321(2001)
- Successfulconversionfromconventionalimmunosuppressiontoanti-CD154monoclonalantibodycostimulatorymoleculeblockadeinrhesusrenalallograftrecipients:C.S.Cho,etal.;Transplantation72,587(2001)
- TreatmentwiththehumanizedCD154-specificmonoclonalantibody,hu5C8,preventsacuterejectionofprimaryskinallograftsinnonhumanprimates:E.A.Elster,etal.;Transplantation72,1473(2001)
- Theeffectofanti-CD40ligandantibodyonBcellsinhumansystemiclupuserythematosus:W.Huang,etal.;Arthr.Rheum.46,1554(2002)
- Humanizedanti-CD154antibodytherapyforthetreatmentofallograftrejectioninnonhumanprimates:H.Xu,etal.;Transplantation74,940(2002)
- AshortcourseofBG9588(anti-CD40ligandantibody)improvesSEROlogicactivityanddecreaseshematuriainpatientswithproliferativelupusglomerulonephritis:D.T.Boumpas,etal.;Arthr.Rheum.48,719(2003)
- AbnormalgerminalcenterreactionsinsystemiclupuserythematosusdemonstratedbyblockadeofCD154-CD40interactions:A.C.Grammer,etal.;J.Clin.Invest.112,1506(2003)
- HumanCD34(+)bloodcellsinduceT-cellunresponsivenesstospecificalloantigensonlyundercostimulatoryblockade:M.Arpinati,etal.;Exp.Hematol.31,31(2003)
- CD154blockadeanddonor-specifictransfusionsinDLA-identicalmarrowtransplantationindogsconditionedwith1-GytotalbodyirrADIation:C.Jochum,etal.;Biol.BloodMarrow.Transplant.13,164(2007)
- EnhancementofTcellactivationbyimmobilizedhu5C8(anti-CD40L)monoclonalantibody:M.Arpinati,etal.;Eur.J.Haematol.80,322(2008)
- Establishmentoflong-termtolerancetoSRBCindogsbyrecombinantcanineCTLA4-Ig:S.S.Graves,etal.;Transplantation88,317(2009)
品牌介绍
Adipogen公司由三个子公司组成，分别是Adipogen,Inc.(韩国),AdipogenSA(瑞士)和 AdipogenCorporation(美国圣地亚哥)。总部设在美国，运营总部在瑞士利斯塔尔。Adipogen公司专门从事生命科学研究试剂的开发，如癌症、免疫、炎症、代谢疾病（糖尿病、肥胖）、干细胞和神经退行性疾病等领域。其重点关注开发创新优质的ELISA试剂盒。另外，也可提供抗体和蛋白产品，Adipogen拥有自己的化学实验室，致力于开发创新型小分子化合物。
联络我们
